摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(5-甲基-2-苯基1,3-氧杂醇-4-烷基)乙酸 | 107367-98-6

中文名称
2-(5-甲基-2-苯基1,3-氧杂醇-4-烷基)乙酸
中文别名
2-(5-甲基-2-苯基-1,3-氧唑)乙酸;2-(5-甲基-2-苯基-1,3-噁唑-4-基)乙酸;2-(5-甲基-2-苯基1,3-氧杂醇-4-烷基)乙酸
英文名称
2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetic acid
英文别名
2-(5-methyl-2-phenyloxazol-4-yl)acetic acid;2-(5-Methyl-2-phenyl-4-oxazolyl)-acetic acid;2-Phenyl-5-methyloxazol-4-ylacetic acid;(5-methyl-2-phenyl-oxazol-4-yl)-acetic acid;4-(2-phenyl-5-methyl)-oxazolyl-acetic acid;2-phenyl-5-methyl-4-oxazoleacetic acid;2-(5-methyl-2-phenyl-1,3-oxazol-3-ium-4-yl)acetate
2-(5-甲基-2-苯基1,3-氧杂醇-4-烷基)乙酸化学式
CAS
107367-98-6
化学式
C12H11NO3
mdl
MFCD00100005
分子量
217.224
InChiKey
XEWJNPORMBGGKZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    131 °C
  • 沸点:
    411.7±37.0 °C(Predicted)
  • 密度:
    1.245±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    63.3
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2934999090

SDS

SDS:5c21b3574a9a023c4686574f53899468
查看
Name: 2-(5-Methyl-2-phenyl-1 3-oxazol-4-yl)acetic acid 97% Material Safety Data Sheet
Synonym:
CAS: 107367-98-6
Section 1 - Chemical Product MSDS Name:2-(5-Methyl-2-phenyl-1 3-oxazol-4-yl)acetic acid 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
107367-98-6 2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)a 97% unlisted
Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 107367-98-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 122 - 123 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H11NO3
Molecular Weight: 217

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 107367-98-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)acetic acid - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 107367-98-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 107367-98-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 107367-98-6 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    新型噻唑烷-2,4-二酮类药物作为有效的高血糖药。
    摘要:
    通过用各种官能团即酮,醇或烯烃部分取代恩格列酮的醚官能团,获得了一系列新的噻唑烷-2,4-二酮。这些化合物可降低遗传性肥胖和胰岛素抵抗的ob / ob小鼠的血糖水平。在链的末端附加基于恶唑基的基团提供了高效的化合物。
    DOI:
    10.1021/jm00088a022
  • 作为产物:
    描述:
    3-(5-甲基-2-苯基-4-恶唑基)丙腈氢氧化钾 作用下, 以 乙醇 为溶剂, 以44%的产率得到2-(5-甲基-2-苯基1,3-氧杂醇-4-烷基)乙酸
    参考文献:
    名称:
    Antidiabetic agents
    摘要:
    本发明提供了式(I)的化合物: 1 其中A、X、Q、Y、B、D、Z和E具有规范中定义的任何值,以及药用可接受的盐,这些化合物作为抗糖尿病药是有用的。还公开了包含一个或多个式I化合物的药物组合物,制备式I化合物的方法,以及用于制备式I化合物的中间体。
    公开号:
    US20030171377A1
点击查看最新优质反应信息

文献信息

  • [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
    申请人:UNIV LEUVEN KATH
    公开号:WO2010142801A1
    公开(公告)日:2010-12-16
    This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
    本发明提供了新型化合物,以及这些新型化合物作为药物的使用,特别是用于预防或治疗神经退行性疾病,更具体地是一些神经系统疾病,例如统称为tauopathies的疾病,以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物,以及制备所述新型化合物的方法。
  • Studies on antidiabetic agents. VII Synthesis and hypoglycemic activity of 4-oxazoleacetic acid derivatives.
    作者:KANJI MEGURO、HIROYUKI TAWADA、YASUO SUGIYAMA、TAKESHI FUJITA、YUTAKA KAWAMATSU
    DOI:10.1248/cpb.34.2840
    日期:——
    As part of a search for new antidiabetic agents, 4-oxazolealkanoic acid derivatives (III) were synthesized and tested for hypoglycemic activity in mice. 4-Oxazoleacetic acids (IIIb) bearing a styryl or a suitable aliphatic hydrocarbon moiety at the 2-position showed potent activity. The synthesis and structure-activity relationships of these compounds are presented.
    作为寻找新型抗糖尿病药物的一部分,合成了4-噁唑烷酮酸衍生物(III),并在小鼠中测试了其降血糖活性。具有2-位为苯乙烯或合适脂肪族烃基的4-噁唑乙酸(IIIb)显示出强大的活性。这些化合物的合成及其构效关系在此呈现。
  • Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
    申请人:——
    公开号:US20030236227A1
    公开(公告)日:2003-12-25
    The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
    该发明提供了在治疗2型糖尿病中有用的药物化合物。这些化合物具有优势,因为它们可以被代谢药物解毒系统迅速代谢。特别地,设计了包含酯基的噻唑烷二酮类似物的化合物。该发明还涉及治疗疾病的方法,如糖尿病,包括给予经设计为能够被血清或细胞内酯酶代谢的化合物的治疗有效组合物。还教授了含酯基的噻唑烷二酮类似物的药物组合物。
  • Novel pyridopyprimidinone derivatives which are HM74A agonists
    申请人:Conte Aurelia
    公开号:US20070275987A1
    公开(公告)日:2007-11-29
    The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R 1 to R 8 , X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.
    这项发明涉及式(I)的新型吡啶吡嘧啶酮衍生物:其中R1至R8、X、Y、m和n如描述和索赔中所定义。本发明的化合物是HM74A激动剂,与烟酸相比具有改进的性能,并可用于治疗和/或预防与HM74A相关的疾病,如脂质代谢异常、动脉粥样硬化、糖尿病、代谢综合征和其他与HM74A相关的疾病。
  • HETARYL-SUBSTITUTED HETEROCYCLES
    申请人:——
    公开号:US20040009877A1
    公开(公告)日:2004-01-15
    The invention relates to novel compounds of formula (I) in which A, B, W, G and Het have the same designation cited in the description. The invention also relates to several methods for the production of said new compounds and the use thereof as pesticides and herbicides. 1
    这项发明涉及公式(I)中的新化合物,其中A、B、W、G和Het具有描述中引用的相同指定。该发明还涉及几种生产这些新化合物的方法以及将其用作杀虫剂和除草剂的用途。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺